![]() Among 9,222 total eligible tests, overall VE among adults aged ≥18 years was 54% (95% CI = 46%–60%) at a median of 52 days after vaccination. Data from the Increasing Community Access to Testing SARS-CoV-2 pharmacy testing program were analyzed to estimate updated COVID-19 vaccine effectiveness (VE) (i.e., receipt versus no receipt of updated vaccination) against symptomatic SARS-CoV-2 infection, including by SGTF result. Reduction or failure of spike gene ( S-gene) amplification (i.e., S-gene target failure ) in real-time reverse transcription–polymerase chain reaction testing is a time-dependent, proxy indicator of JN.1 infection. ![]() XBB lineages predominated through December 2023, when JN.1 became predominant in the United States. These variants have amino acid substitutions that might increase escape from neutralizing antibodies. During fall 2023, XBB lineages co-circulated with JN.1, an Omicron BA.2.86 lineage that emerged in September 2023. On September 12, 2023, CDC’s Advisory Committee on Immunization Practices recommended updated 2023–2024 (updated) COVID-19 vaccination with a monovalent XBB.1.5–derived vaccine for all persons aged ≥6 months to prevent COVID-19, including severe disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |